1. Home
  2. Category
  3. Diagnosis and Screening

Treatment Decision Making

Supportive Care

Scalp Cooling: Implementing a Cold Cap Program at a Community Breast Health Center

Mary Heery
Shaira Cohen
Zarek Mena
CJON 2019, 23(3), 237-241 DOI: 10.1188/19.CJON.237-241
Many patients undergoing cancer treatment experience alopecia. To support patients, scalp cooling programs can be coordinated and implemented to educate patients and their caregivers on the benefits of and best practices for using cold caps to limit the extent of hair loss. In addition, fundraising...
0
No votes yet
Read this Article
Article

Mental Health and Substance Use Disorders in Patients Diagnosed With Cancer: An Integrative Review of Healthcare Utilization

Joanna Woersching
Janet H. Van Cleave
Judith Haber
Deborah Chyun
ONF 2019, 46(3), 365-383 DOI: 10.1188/19.ONF.365-383
Problem Identification: The impact of mental health disorders (MHDs) and substance use disorders (SUDs) on healthcare utilization (HCU) in patients with cancer is an understudied phenomenon. Literature Search: A literature search of studies published prior to January 2018 that examined HCU in...
0
No votes yet
Read this Article
Article

Enhancing Advance Care Planning Conversations by Nurses in a Bone Marrow Transplantation Unit

Shigeko (Seiko) Izumi
Malinda Burt
Jennifer Smith
Keren McCord
Erik K. Fromme
ONF 2019, 46(3), 288-297 DOI: 10.1188/19.ONF.288-297
Objectives: To describe the impact of advance care planning (ACP) education on nurses’ confidence in ACP knowledge and practice and to identify barriers to facilitate ACP conversation in a bone marrow transplantation unit. Sample & Setting: 60 nurses working in the bone marrow transplant unit...
0
No votes yet
Read this Article
Essentials

Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura

Katie Atkinson
CJON 2019, 23(2), 212-216 DOI: 10.1188/19.CJON.212-216
The thrombopoietin receptor agonists, eltrombopag and romiplostim, are second-line agents used to treat chronic immune thrombocytopenia purpura (ITP) in adults and children. ITP is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in...
0
No votes yet
Read this Article
Online Exclusive Article

Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma

Heather Ugolini
Jennifer Bryan
Meliessa Hennessy
Howard L. Kaufman
Sandra P. D’Angelo
CJON 2019, 23(1), E1-E9 DOI: 10.1188/19.CJON.E1-E9
Background: Metastatic Merkel cell carcinoma (mMCC) is a rare skin cancer with poor prognosis. Avelumab is the first approved treatment option for patients with mMCC. Immune checkpoint inhibitors, such as avelumab, are associated with unique toxicities that can be effectively addressed with prompt...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.